



## State of the Art in Alzheimer's Disease Pathology

Guest Editor:

**Prof. Dr. Amit Singh**

Department of Biology, University  
of Dayton, Dayton, OH 45469,  
USA

Deadline for manuscript  
submissions:

**closed (20 January 2024)**

### Message from the Guest Editor

Dear Colleagues,

Alzheimer's disease (AD) is the most common age-related progressive neurodegenerative disorder, and its pathology involves a long preclinical period. The amyloid  $\beta$  ( $A\beta$ ) peptides, total tau protein (T-tau), and tau protein phosphorylated at threonine 181 (P-tau(181)) are considered surrogate biomarkers of Alzheimer's disease pathology. Despite advances in preclinical and clinical studies of AD in recent years, its pathogenesis is still unclear and effective methods of treatment are lacking. The aim of this Special Issue is to highlight the recent advances in research by collecting original articles and reviews that present the current developments in AD biomarkers, AD pathogenesis, and AD-related therapeutic strategies.

Prof. Dr. Amit Singh  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Stephen D. Meriney

Department of Neuroscience,  
University of Pittsburgh,  
Pittsburgh, PA 15260, USA

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYINDEX, CAPus / SciFinder, and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the second half of 2023).

## Contact Us

Brain Sciences Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/brainsci](http://mdpi.com/journal/brainsci)  
[brainsci@mdpi.com](mailto:brainsci@mdpi.com)  
[X@BrainSci\\_MDPI](https://twitter.com/BrainSci_MDPI)